FOLH1 and metastatic prostate carcinoma: Similarly, a Phase I trial, focused on the immunization of castration-resistant metastatic prostate cancer (CRPC) patients, tested the efficacy of propagation-defective alphavirus particles expressing the prostate-specific membrane antigen (PSMA).